Miguel Gil

Miguel Gil

Auto-generated profile, based on publicly available information

Miguel Gil

Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria Agencia Española de Medicamentos y Productos Sanitarios Madrid Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
MMMiguel‐Angel Maciá‐Martínez
Miguel‐Angel Maciá‐Martínez
MGMiguel Gil
Miguel Gil
CHConsuelo Huerta
Consuelo Huerta
EMElisa Martín‐Merino
Elisa Martín‐Merino
AÁArturo Álvarez
Arturo Álvarez
TTthe BIFAP Team
the BIFAP Team

17 November 2021 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
LRLuis A. García Rodríguez
Luis A. García Rodríguez
LSLucia Cea Soriano
Lucia Cea Soriano
Francisco J. De AbajoFrancisco J. De Abajo
Francisco J. De Abajo
FVFrancesca Valent
Francesca Valent
JHJesper Hallas
Jesper Hallas
DGDavid Gaist
David Gaist
Purpose: To evaluate time trends in the prevalence of antithrombotic and statin use in four European countries. Methods: Using population-based data from the United Kingdom, Denmark, Spain and Italy between 2010 and 2018, we calculated standardized annual prevalence proportions of antithrombotics and statin use, and changes in prevalence proportions (2018 vs. 2010). Results: Prevalence proportion of statins increased from 24.8% to 24.6% (UK), 21.0% to 22.3% (Region of Southern Denmark [RSD]), 12.9% to 14.3% (Udine, Italy), and 20.3% to 23.2% (Spain). Prevalence proportions of antithrombotics declined in all four countries: 18.7% to 15.9% (UK; − 2.8% points), 18.9% to 18.1% (RSD; − 0.8% points), 17.7% to 16.6% (Udine; − 1.1% points) and 15.0% to 13.6% (Spain; − 1.4% points). These declines were driven by reductions in low-dose aspirin use: 15.3% to 8.9% (UK; − 6.4% points), 16.3% to 9.5% (RSD; − 6.8% points), 13.5% to 11.6% (Udine; − 1.9% points), and 10.2% to 8.8% (Spain; − 1.4% points). In the UK, low-dose aspirin use declined from 9.1% to 4.3% (− 4.8% points) for primary CVD prevention, and from 49.6% to 36.9% (− 12.7% points) for secondary prevention. Oral anticoagulant use gradually increased but did not fully account for the decrease in low-dose aspirin use. Conclusions: Antithrombotic use in the UK, RSD, Udine and Spain declined between 2010 and 2018, driven by a reduction in use of low-dose aspirin that is not completely explained by a gradual increase in OAC use. Use of statins remained constant in the UK, and increased gradually in the RSD, Udine and Spain.

12 December 2018 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
MGMiguel Gil
Miguel Gil
ARAntonio Rodríguez-Miguel
Antonio Rodríguez-Miguel
HMHéctor Montoya‐Catalá
Héctor Montoya‐Catalá
RGRocío González González
Rocío González González
AÁArturo Álvarez‐Gutiérrez
Arturo Álvarez‐Gutiérrez
Francisco J. De AbajoFrancisco J. De Abajo
Francisco J. De Abajo

8 November 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
SRSara Rodríguez-Martín
Sara Rodríguez-Martín
DBDiana Barreira-Hernández
Diana Barreira-Hernández
MGMiguel Gil
Miguel Gil
Alberto García-LledoAlberto García-Lledo
Alberto García-Lledo
LILaura Izquierdo-Esteban
Laura Izquierdo-Esteban
Francisco J. De AbajoFrancisco J. De Abajo
Francisco J. De Abajo
Background and objectives: To assess the relationship between influenza vaccination in the general population and risk of a first ischemic stroke (IS) during pre-epidemic, epidemic and post-epidemic periods. Methods: A nested case-control study was carried out in a Spanish primary care database over 2001-2015. Subjects aged 40-99 years with at-least 1-year registry and no history of stroke or cancer were selected to conform the source cohort, from which incident IS cases were identified and classified as cardioembolic or non-cardioembolic. Five controls per case were randomly selected, individually matched with cases for exact age, sex and date of stroke diagnosis (index date). A patient was considered vaccinated when he/she had a recorded influenza vaccination at least 14 days before the index date within the same season. Adjusted odds ratios (AOR) and their respective 95% confidence intervals (CI) were computed through a conditional logistic regression. Pneumococcal vaccination was used as a negative control. Results: From a cohort of 3,757,621 patients, we selected 14,322 incident IS cases (9,542 non-cardioembolic and 4,780 cardioembolic) and 71,610 matched controls. Of them, 41.4% and 40.5%, respectively, were vaccinated yielding a crude OR of 1.05(95%CI:1.01-1.10). Vaccinated subjects presented a higher prevalence of vascular risk factors, diseases and comedication than non-vaccinated and, after full adjustment, the association of influenza vaccination with IS yielded an AOR of 0.88(95%CI:0.84-0.92) was found, appearing early (AOR15-30 days=0.79;95%CI:0.69-0.92) and slightly declining over time (AOR>150 days=0.92;95%CI:0.87-0.98). A reduced risk of similar magnitude was observed with both types of IS, in the three epidemic periods and in all subgroups analyzed (men, women, subjects below and over 65 years of age, and subjects with intermediate and high vascular risk). By contrast, pneumococcal vaccination was not associated with a reduced risk of IS (AOR=1.08;95%CI:1.04-1.13). Discussion: Results are compatible with a moderate protective effect of influenza vaccine on IS appearing early after vaccination. The finding that a reduced risk was also observed in pre-epidemic periods suggests that either the “protection” is not totally linked to prevention of influenza infection, or it may be partly explained by unmeasured confounding factors.

1 May 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
RARasha Alqdwah-Fattouh
Rasha Alqdwah-Fattouh
SRSara Rodríguez-Martín
Sara Rodríguez-Martín
DBDiana Barreira-Hernández
Diana Barreira-Hernández
LILaura Izquierdo-Esteban
Laura Izquierdo-Esteban
MGMiguel Gil
Miguel Gil
Francisco J. De AbajoFrancisco J. De Abajo
Francisco J. De Abajo
Background: Multiple studies have reported that the use of selective serotonin reuptake inhibitors (SSRIs) is associated with an increased risk of ischemic stroke; however, this finding may be the result of a confounding by indication. We examined the association using different approaches to minimize such potential bias. Methods: A nested case-control study was carried out in a Spanish primary health-care database over the study period 2001 to 2015. Cases were patients sustaining an ischemic stroke with no sign of cardioembolic or unusual cause. For each case, up to 5 matched controls (for exact age, sex, and index date) were randomly selected. Antidepressants were divided in 6 pharmacological subgroups according to their mechanism of action. The current use of SSRIs (use within a 30-day window before index date) was compared with nonuse, past use (beyond 365 days) and current use of other antidepressants through a conditional logistic regression model to obtain adjusted odds ratios and 95% CI. Only initiators of SSRIs and other antidepressants were considered. Results: A total of 8296 cases and 37 272 matched controls were included. Of them, 255 (3.07%) were current users of SSRIs among cases and 834 (2.24%) among controls, yielding an adjusted odds ratio of 1.14 (95% CI, 0.97–1.34) as compared with nonusers, 0.94 (95% CI, 0.77–1.13) as compared with past-users and 0.74 (95% CI, 0.58–0.93) as compared with current users of other antidepressants. No relevant differences were found by duration (≤1, >1 year), sex, age (<70, ≥70 years old) and background vascular risk. Conclusions: The use of SSRIs was not associated with an increased risk of noncardioembolic ischemic stroke. On the contrary, as compared with other antidepressants, SSRIs appeared to be protective.

23 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMarietta Rottenkolber
Marietta Rottenkolber
EVEef Voogd
Eef Voogd
Liset van DijkLiset van Dijk
Liset van Dijk
PPPaola Primatesta
Paola Primatesta
CBClaudia Becker
Claudia Becker
SSSven Schmiedl
Sven Schmiedl
Inhaled, long-acting beta-2-adrenoceptor agonists (LABA) have well-established roles in asthma and/or COPD treatment. Drug utilisation patterns for LABA have been described, but few studies have directly compared LABA use in different countries. We aimed to compare the prevalence of LABA-containing prescriptions in five European countries using a standardised methodology. A common study protocol was applied to seven European healthcare record databases (Denmark, Germany, Spain, the Netherlands (2), and the UK (2)) to calculate crude and age- and sex-standardised annual period prevalence rates (PPRs) of LABA-containing prescriptions from 2002–2009. Annual PPRs were stratified by sex, age, and indication (asthma, COPD, asthma and COPD). From 2002–2009, age- and sex-standardised PPRs of patients with LABA-containing medications increased in all databases (58.2%–185.1%). Highest PPRs were found in men ≥ 80 years old and women 70–79 years old. Regarding the three indications, the highest age- and sex-standardised PPRs in all databases were found in patients with “asthma and COPD” but with large inter-country variation. In those with asthma or COPD, lower PPRs and smaller inter-country variations were found. For all three indications, PPRs for LABA-containing prescriptions increased with age. Using a standardised protocol that allowed direct inter-country comparisons, we found highest rates of LABA-containing prescriptions in elderly patients and distinct differences in the increased utilisation of LABA-containing prescriptions within the study period throughout the five European countries.